Radiomics predicts risk of cachexia in advanced NSCLC patients treated with immune checkpoint inhibitors.

ABSTRACT:

Background

Approximately 50% of cancer patients eventually develop a syndrome of prolonged weight loss (cachexia), which may contribute to primary resistance to immune checkpoint inhibitors (ICI). This study utilised radiomics analysis of ¹⁸F-FDG-PET/CT images to predict risk of cachexia that can be subsequently associated with clinical outcomes among advanced non-small cell lung cancer (NSCLC) patients treated with ICI.

Methods

Baseline (pre-therapy) PET/CT images and clinical data were retrospectively curated from 210 ICI-treated NSCLC patients from two institutions. A radiomics signature was developed to predict the cachexia with PET/CT images, which was further used to predict durable clinical benefit (DCB), progression-free survival (PFS) and overall survival

SUBMITTER: Mu W 

PROVIDER: S-EPMC8292339 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature